You could be based in a university, Electric Literature of 119139-23-0, combining chemical research with teaching; in a pharmaceutical company, working on developing and trialing new drugs; or in a public-sector research center, helping to ensure national healthcare provision keeps pace with new discoveries. 119139-23-0, name is 3,4-Di(1H-indol-3-yl)-1H-pyrrole-2,5-dione. In an article，Which mentioned a new discovery about 119139-23-0
Tubulin binding compounds represent one of the most attractive targets for anticancer drug development. They broadly fall into two categories viz., tubulin polymerization inhibitors, which block microtubule growth and destabilize microtubules like vinca alkaloids and cryptophycins, and the others, which polymerize microtubules into hyperstable forms represented by family of taxanes. In this context, we aimed at design and synthesis of cryptophycins based macrocyclic depsipeptides, which are synthetically more accessible, however have the basic information to target tubulins and establish structure activity relationship (SAR). Thus, a new class of cryptophycins based marocyclic depsipeptides with a truncated epoxide chain were synthesized as potential tubulin inhibitors. The resultant lead analogues 15a and 16a exhibited good anti-cancer activity, induced apoptosis, caused block/delay in cell cycle as well as significantly reduced the expression of alpha- and beta-tubulins. Molecular modelling studies show that 15a and 16a bind in the same domain as that of cryptophycins.
Enzymes are biological catalysts that produce large increases in reaction rates and tend to be specific for certain reactants and products. In my other articles, you can also check out more blogs about 119139-23-0
Reference：
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis—I. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis